60 related articles for article (PubMed ID: 38597130)
41. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
42. Cancer immunotherapy using checkpoint blockade.
Ribas A; Wolchok JD
Science; 2018 Mar; 359(6382):1350-1355. PubMed ID: 29567705
[TBL] [Abstract][Full Text] [Related]
43. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
Zhang C; Oberoi P; Oelsner S; Waldmann A; Lindner A; Tonn T; Wels WS
Front Immunol; 2017; 8():533. PubMed ID: 28572802
[TBL] [Abstract][Full Text] [Related]
44. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Sharma P; Hu-Lieskovan S; Wargo JA; Ribas A
Cell; 2017 Feb; 168(4):707-723. PubMed ID: 28187290
[TBL] [Abstract][Full Text] [Related]
45. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
46. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
47. Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010.
Meza R; Meernik C; Jeon J; Cote ML
PLoS One; 2015; 10(3):e0121323. PubMed ID: 25822850
[TBL] [Abstract][Full Text] [Related]
48. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Tumeh PC; Harview CL; Yearley JH; Shintaku IP; Taylor EJ; Robert L; Chmielowski B; Spasic M; Henry G; Ciobanu V; West AN; Carmona M; Kivork C; Seja E; Cherry G; Gutierrez AJ; Grogan TR; Mateus C; Tomasic G; Glaspy JA; Emerson RO; Robins H; Pierce RH; Elashoff DA; Robert C; Ribas A
Nature; 2014 Nov; 515(7528):568-71. PubMed ID: 25428505
[TBL] [Abstract][Full Text] [Related]
49. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Karbach J; Nemeth MJ; Taverna P; Karpf AR; Griffiths EA
Leuk Res; 2014 Nov; 38(11):1332-41. PubMed ID: 25260825
[TBL] [Abstract][Full Text] [Related]
50. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Taube JM; Klein A; Brahmer JR; Xu H; Pan X; Kim JH; Chen L; Pardoll DM; Topalian SL; Anders RA
Clin Cancer Res; 2014 Oct; 20(19):5064-74. PubMed ID: 24714771
[TBL] [Abstract][Full Text] [Related]
51. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
[TBL] [Abstract][Full Text] [Related]
52. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
53. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Dong M; Ning ZQ; Xing PY; Xu JL; Cao HX; Dou GF; Meng ZY; Shi YK; Lu XP; Feng FY
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1413-22. PubMed ID: 22362161
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Wen W; Zhang Y; Zhang H; Chen Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):969-978. PubMed ID: 35771261
[TBL] [Abstract][Full Text] [Related]
55. Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.
Zhang Y; Chen Z; Liu Y; Han L; Jiang W; Wang Q; Shi J; Lu L; Li J; Zhang M; Huang Y; Yang Y; Hou X; Zhang L; Li J; Fang W; Chen G
Cancer Med; 2024 Apr; 13(7):e7175. PubMed ID: 38597130
[TBL] [Abstract][Full Text] [Related]
56. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
57. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
Wang C; Yu X; Wang W
Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
